Eli Lilly’s Jaypirca (pirtobrutinib) has been recommended by the European Medicines Agency’s (EMA) human medicines committee ...

The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.

In the oncology segment, Pirtobrutinib (Jaypirca) received accelerated approval for chronic lymphocytic leukemia in the U.S. in 2023, and Mantle cell lymphoma in the U.S. in 2023, the EU in 2023, and ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

"Unsurprisingly, pirtobrutinib [Jaypirca, Eli Lilly & Co.] was superior to the comparator arm in terms of progression-free survival," Woyach, professor in the division of hematology at The Ohio ...

In the past two years, Lilly has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Its new drugs contributed significantly to its top-line growth in 2024. Lilly is also making ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after acalabrutinib and venetoclax/rituximab. JAIN: In…December 2023, pirtobrutinib ...

Overseen by the renowned immunologist Dr. Carl June, it showed the edited genes had a sustained ability to attack and kill tumors. CRISPR is a revolutionary method of gene editing that allows ...